ArticleBMC neurology2022
Primary large B-cell lymphoma of the central nervous system with positive NMDAR antibody: a case report.
Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Extraparenchymal Brain Lesions in Anti-NMDAR Encephalitis Leading to Primary Leptomeningeal Lymphoma: A Rare Evolution with Diagnostic Implications.Internal medicine (Tokyo, Japan) · 2026Article
- NMDAR-Antibody Encephalitis Diagnosed With Primary Central Nervous System Lymphoma: A Case Series.Annals of clinical and translational neurology · 2025Article
- Development of anti-NMDA receptor encephalitis in a patient with multiple sclerosis.BMJ case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundN-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate (Glu) receptor that is widely expressed in the central nervous system (CNS), mainly in the hippocampus. We present a case in which the patient had atypical clinical manifestations and was positive for anti-NMDAR antibodies. CASE PRESENTATION: A 40-year-old male was admitted to the hospital with "dizziness and double vision for 2 months". At admission, the patient was lethargic, had short-term memory loss, exhibited loss of orientation (time, place, and person) and calculation ability, and had limited left eye abduction. After admission, serum anti- NMDAR antibody was 1:32, and cerebrospinal fluid was 1:1. Magnetic resonance imaging (MRI) revealed diffuse abnormal signals in the bilateral basal ganglia, thalamus, brainstem, hippocampus, and temporal lobe, with patchy and heterogeneous enhancement. A stereotactic brain biopsy was performed, and the pathological results indicated normal brain tissue. Preliminary diagnosis suggested anti-NMDAR antibody encephalitis. The patient was treated with methylprednisolone combined with intravenous gamma globulin; the symptoms were alleviated, and the patient was discharged. Two months later, the patient's symptoms worsened, and a second stereotactic brain biopsy was performed. The pathological results showed that the patient had primary diffuse large B-cell lymphoma of the CNS, and the patient was transferred to the Department of Hematology and received chemotherapy combined with rituximab. The patient was in stable condition.
conclusionsWhen the primary CNS diffuses large B-cell lymphoma is associated with autoimmune encephalitis, it is very easy to be misdiagnosed. The diagnosis should not be based on the pathological examination that was performed in the early stage of the disease. Therefore, in the diagnosis of immune diseases caused by nervous system infections, it is necessary to dynamically observe the evolution of the disease, perform differential diagnoses when necessary, and ultimately improve our understanding of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.